Antibodies for targeted gene therapy: Extracellular gene targeting and intracellular expression

Advanced Drug Delivery Reviews

Volumn 31, Issue 1-2, 1998, Pages 153-170

  Dana Jones, Susan ^a   Marasco, Wayne A ^b  

^a IntraImmune Therapies Inc   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antibody engineering; Gene delivery; Intracellular immunization; Targeted immunotherapy

Indexed keywords

ANTIBODIES; GENETIC ENGINEERING; IMMUNIZATION;

ANTIBODY ENGINEERING; INTRACELLULAR IMMUNIZATION;

CONTROLLED DRUG DELIVERY;

AMYLOID PRECURSOR PROTEIN; ANTIBODY; ASIALOGLYCOPROTEIN RECEPTOR; FIBROBLAST GROWTH FACTOR; IMMUNOTOXIN; INTRACELLULAR ANTIBODY; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; INFECTION; LIVER CELL; LUNG DISEASE; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC ANIMAL; TRANSPLANTATION;

EID: 0032489849     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00099-9     Document Type: Review

References (100)

1. Griffiths A.D., Malmqvist M., Marks J.D., Bye J.M., Embleton M.J., McCafferty J., Baier M., Holliger K.P., Gorick B.D., Hughes-Jones N.C., Hoogenboom H., Winter G. Human anti-self antibodies with high specificity from phage display libraries. EMBO J. 12:1993;725-734.
2. Vaughan T.J., Williams A.J., Pritchard K., Osbourn J.K., Pope A.R., Earnshaw J.C., McCafferty J., Hodits R.A., Wilton J., Johnson K.S. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nature Biotechnol. 14:1996;309-314.
3. Marks C., Marks J.D. Phage libraries - A new route to clinical useful antibodies. New Engl. J. Med. 335:1996;730-733.
4. Huston J.S., Levinson D., Mudgett-Hunter M., Tai M.-S., Novotny J., Margolies M.N., Ridge R.J., Bruccoleri R.E., Haber E., Crea R., Oppermann H. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA. 85:1988;5879-5883.
5. Bird R.E., Hardman K.D., Jacobson J.W., Johnson S., Kaufman B.M., Lee S.-M., Lee T., Pope S.H., Riordan G.S., Whitlow M. Single-chain antigen-binding proteins. Science. 242:1988;423-426.
6. Reilly R.M., Sandhu J., Alvarez-Diez T.M., Gallinger S., Kirsh J., Stern H. Problems of delivery of monoclonal antibodies. Clin. PharmacoKinet. 26:1995;126-142.
7. Harrison K.A., Tempero M.A. Diagnostic use of radiolabeled antibodies for cancer. Oncology. 9:1995;625-631.
8. Williams L.E., Liu A., Wu A.M., Odom-Maryon T., Chai A., Raubitschek A.A., Wong J.Y.C. Figures of merit (FOMs) for imaging and therapy using monoclonal antibodies. Med. Phys. 22:1995;2025-2027.
9. H3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 36:1996;3055-3061.
10. Wu A.M., Chen W., Raubitschek A., Williams L.E., Neumaier M., Fischer R., Hu S-Z., Odom-Maryon T., Wong J.Y.C., Shively J.E. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology. 2:1996;21-36.
11. King D.J., Turner A., Farnsworth A.P.H., Adair J.R., Owens R.J., Pedley R.B., Baldock D., Proudfoot K.A., Lawson A.D.G., Beeley N.R.A., Millar K., Millican T.A., Boyce B.Z., Antoniw P., Mountain A., Begent R.H.J., Shochat D., Yarranton G.T. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res. 54:1994;6176-6185.
12. Press O.W., Vitetta E.S., Farr A.G., Hansen J.A., Martin P.J. Evaluation of ricin A-chain immunotoxins directed against human T cells. Cellular Immunol. 102:1986;10-20.
13. Siegall C.B., Chaudhary V.K., FitzGerald D.J., Pastan I. Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J. Biol. Chem. 264:1989;14256-14261.
14. Press O.W., Martin P.J., Thorpe P.E., Vitetta E.S. Ricin A-chain containing immunotoxins directed against different epitopes in the CD2 molecule differ in their ability to kill normal and malignant T cells. J. Immunol. 141:1988;4410-4417.
15. Wargalla U.C., Reisfeld R.A. Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. Proc. Natl. Acad. Sci. USA. 86:1989;5146-5150.
16. Lappi D.A., Baird A. Mitotoxins: growth factor-targeted cytotoxic molecules. Prof. Growth Fact. Res. 2:1990;223-236.
17. Beitz J.G., Davol P., Clark J.W., Kato J., Medina M., Frackelton A.R. Jr., Lappi D.A., Baird A., Calabresi P. Antitumor activity of basic fibroblast growth factor - saporin mitotoxin in vitro and in vivo. Cancer Res. 52:1992;227-230.
18. Pickering J.G., Bacha P.A., Weir L., Jekanowski J., Nichols J.C., Isner J.M. Prevention of smooth muscle cell outgrowth from human atherosclerotic plaque by a recombinant cytotoxin specific for the epidermal growth factor receptor. J. Clin. Invest. 91:1993;724-729.
19. Casscells W., Lappi D.A., Olwin B.B., Wai C., Siegman M., Speir E.H., Sasse J., Baird A. Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors. Proc. Natl. Acad. Sci. USA. 89:1992;7159-7163.
20. Pastore C.J., Isner J.M., Bacha P.A., Kearney M., Pickering J.G. Epidermal growth factor receptor-targeted cytotoxin inhibits neointimal hyperplasia in vivo. Circulat. Res. 77:1995;519-529.
21. Mattar S.G., Hanson S.R., Pierce G.F., Chen C., Hughes J.D., Cook J.E., Shen C., Noe B.A., Suwyn C.R., Scott J.R., Lumsden A.B. Local infusion of FGF-saporin reduces intimal hyperplasia. J. Surg. Res. 60:1996;339-344.
22. Pai L.H., Pastan I. Immunotoxin therapy for cancer. J. Am. Med. Assoc. 269:1993;78-81.
23. Gottstein C., Schön G., Tawadros S., Kube D., Wargalla-Plate U.C., Hansmann M.L., Wacker H.H., Berthold F., Diehl V., Engert A. Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model. Cancer Res. 54:1994;6186-6193.
24. Pai L.H., Bookman M.Z., Ozols R.F., Young R.C., Smith J.W., Longo D.L., Gould B., Frankel A., McClay E.F., Howell S.et al. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J. Clin. Oncol. 9:1991;2095-2103.
25. Pai L.H., Wittes R., Setser A., Willingham M.C., Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: An antibody linked to Pseudomonas exotoxin. Nature Med. 2:1996;350-353.
26. 1. J. Immunol. 135:1985;1530-1535.
27. Courtenay-Luck N.S., Epenetos A.A., Moore R., Larche M., Pectasides D., Dhokia B., Ritter M.A. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res. 46:1986;6489-6493.
28. Selvaggi K., Saria E.A., Schwartz R., Vlock D.R., Ackerman S., Wendel N., Kirkwood J.M., Jones H., Ernstoff M.S. Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporin A in patients with metastatic melanoma. J. Immunother. 13:1993;201-207.
29. Stankovics J., Crane A.M., Andrews E., Wu C.H., Wu G.Y., Ledley F.D. Overexpression of human methylmalonyl CoA mutase in mice after in vivo gene transfer with asialoglycoprotein/polylysine/DNA complexes. Hum. Gene Ther. 5:1994;1095-1104.
30. Chen S-Y., Zani C., Khouri Y., Marasco W.A. Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Ther. 2:1995;116-123.
31. *. J. Biol. Chem. 271:1996;33647-33653.
32. - immunodeficient patients. Science. 270:1995;470-475.
33. - SCID: initial trial results after 4 years. Science. 270:1995;475-480.
34. Grossman M., Raper S.E., Kozarsky K., Stein E.A., Engelhardt J.F., Muller D., Lupien P.J., Wilson J.M. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat. Genet. 6:1994;335-341.
35. Bahner I., Kerns K., Hao Q.L., Smogorzewska E.M., Kohn D.B. Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture. J. Virol. 70:1996;4352-4360.
36. Ohi S., Kim B.C. Synthesis of human globin polypeptides mediated by recombinant adeno-associated virus vectors. J. Pharm. Sci. 85:1996;274-281.
37. Ledley F.D. Non-viral gene therapy: the promise of genes as pharmaceutical products. Hum. Gene Ther. 6:1995;1129-1144.
38. Somia N.V., Zoppé M., Verma I.M. Generation of targeted retroviral vectors by using single-chain variable fragment: An approach to in vivo gene delivery. Proc. Natl. Acad. Sci. USA. 92:1995;7570-7574.
39. Fominaya J., Wels W. Target cell-specific DNA transfer mediated by a chimeric multidomain protein. J. Biol. Chem. 271:1996;10560-10568.
40. Curiel D.T., Agarwal S., Wagner E., Cotten M. Adenovirus enhancement of transferrin-polylysine-mediated gene delivery. Proc. Natl. Acad. Sci. USA. 88:1991;8850-8854.
41. Cristiano R.J., Smith L.C., Kay M.A., Brinkley B.R., Woo S.L.C. Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc. Natl. Acad. Sci. USA. 90:1993;11548-11552.
42. Michael S.I., Curiel D.T. Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway. Gene Ther. 1:1994;223-232.
43. Perales J.C., Ferkol T., Beegen H., Ratnoff O.D., Hanson R.W. Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc. Natl. Acad. Sci. USA. 91:1994;4086-4090.
44. Batra R.K., Wang-Johanning F., Wagner E., Garver R.I., Curiel D.T. Receptor-mediated gene delivery employing lectin-binding specificity. Gene Ther. 1:1994;255-260.
45. Ferkol T., Kaetzel C.S., Davis P.B. Gene transfer into respiratory epithelial cells by targeting the polymeric immunoglobulin receptor. J. Clin. Invest. 92:1993;2394-2400.
46. Dunbar C.E. Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease. Annu. Rev. Med. 47:1996;11-20.
47. Kohn, D.B., Weinberg, K.I., Nolta, J.A., Heiss, L.N., Lenarsky, C., Crooks, G.M., Hanley, M.E., Annett, G., Brooks, J.S., El-Khoureiy, Lawrence, K., Wells, S., Moen, R.C., Bastian, J., Williams-Herman, D.E., Elder, M., Wara, D., Bowen, T., Hershfield, M.S., Mullen, C.A., Blaese, R.M., Parkman, R. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat. Med., (1995) 1017-1023.
48. Licht T., Aksentijevich I., Gottesman M.M., Pastan I. Efficient expression of functional human MDR1 gene in murine bone marrow after retroviral transduction of purified hematopoietic stem cells. Blood. 86:1995;111-121.
49. Larochelle A., Vormoor J., Lapidot T., Sher G., Furukawa T., Li Q., Shultz L.D., Olivieri N.F., Stamatoyannopoulos G., Dick J.E. Engraftment of immune-deficient mice with primitive hematopoietic cells from β-thalassemia and sickle cell anemia patients: implications for evaluating human gene therapy protocols. Hum. Mol. Genet. 4235:1995;163-172.
50. Karlsson S., Correll P.H., Xu L. Gene transfer and bone marrow transplantation with special reference to Gaucher's disease. Bone Marrow Transplant. 11:1993;124-127.
51. Smith C. Retroviral vector-mediated gene transfer into hematopoietic cells: prospects and issues. J. Hematother. 1:1992;155-166.
52. Brenner M.K., Rill D.R., Holladay M.S., Heslop H.E., Moen R.C., Buschie M., Krance R.A., Santana V.M., Anderson W.F., Ihle J.N. Gene marking to determine whether autologous marrow infusion restores long-term haemopolesis in cancer patients. Lancet. 342:1993;1134-1137.
53. Szilvassy S.J., Cory S. Efficient retroviral gene transfer to purified long-term repopulating hematopoietic stem cells. Blood. 84:1994;74-83.
54. Schwarzenberger P., Spence S.E., Gooya J.M., Michiel D., Curiel D.T., Ruscetti F.W., Keller J.R. Targeted gene transfer to human hematopoietic progenitor cell lines through the c-kit receptor. Blood. 87:1996;472-478.
55. Andrews R.G., Singer J.W., Bernstein I.D. Human hematopoietic precursors in long-term culture: single CD34+ cells that lack detectable T cell, B cell, and myeloid cell antigens produce multiple colony-forming cells when cultured with marrow stromal cells. J. Exp. Med. 172:1990;355-358.
56. DiGiusto D., Chen S., Combs J., Webb S., Namikawa R., Tsukamoto A., Chen B.P., Galy A.H. Human fetal bone marrow early progenitors for T, B and myeloid cells are found exclusively in the population expression high levels of CD34. Blood. 84:1994;421-432.
57. Lemoli R.M., Fortuna A., Motta M.R., Rizzi S., Giudice V., Nannetti A., Martinelli G., Cavo M., Amabile M., Mangianti S., Fogli M., Conte R., Tura S. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood. 87:1996;1625-1634.
58. Crystal R.G. Transfer of genes to humans: early lessons and obstacles to success. Science. 270:1995;404-410.
59. Yang Y., Nunes F.A., Berencsi K., Furth E.E., Gönczöl E., Wilson J.M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA. 91:1994;4407-4411.
60. McCoy R.D., Davidson B.L., Roessler B.J., Huffnagle G.B., Janich S.L., Laing T.J., Simon R.H. Pulmonary inflammation induced by incomplete or inactivated adenoviral particles. Hum. Gene Ther. 6:1995;1553-1560.
61. Rojanasakul Y., Wang L.Y., Malanga C.J., Ma J.K.H., Liaw J. Targeted gene delivery to alveolar macrophages via Fc receptor-mediated endocytosis. Pharma. Res. 11:1994;1731-1736.
62. Ferkol T., Perales J.C., Eckman E., Kaetzel C.S., Hanson R.W., Davis P.B. Gene transfer into the airway epithelium of animals by targeting the polymeric immunoglobulin receptor. J. Clin. Invest. 95:1995;493-502.
63. Marasco W.A., Haseltine W.A., Chen S-Y. Design, intracellular expression, and activity of a human anti-HIV gp120 single chain antibody. Proc. Natl. Acad. Sci. 90:1993;7889-7893.
64. Biocca S., Ruberti F., Tafani M., Pierandrei-Amaldi P., Cattaneo A. Redox state of single chain Fv fragments targeted to the endoplasmic reticulum, cytosol, and mitochondria. Bio/Technology. 13:1995;1110-1115.
65. Richardson J.H., Sodroski J.G., Waldmann T.A., Marasco W.A. Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. Proc. Natl. Acad. Sci. 92:1995;3137-3141.
66. Deshane J., Cabrera C., Grim J.E., Siegal G.P., Pike J., Alvarez R.D., Curiel D.T. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol. Oncol. 59:1995;8-14.
67. Graus-Porta D., Beerli R.R., Hynes N.E. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs neu differentiation factor and epidermal growth factor signaling. Molec. Cell Biol. 15:1995;1182-1191.
68. Richardson J., Marasco W.A. Intracellular antibodies: development and therapeutic potential. Trends Biotechnol. 13:1995;306-310.
69. Mhashilkar A.M., Bagley J., Chen S-Y., Szilvay A.M., Helland D.G., Marasco W.A. Inhibition of HIV-1 tat-mediated LTR transactivation and HIV-1 infection by anti-tat single chain intrabodies. EMBO J. 14:1995;1542-1551.
70. Levin R., Mhashilkar A.M., Dorfman T., Bukovsky A., Zani C., Bagley J., Hinkula J., Niedrig M., Albert J., Wahren B., Göttlinger H.G., Marasco W.A. Inhibition of HIV-1 integration and infectious virus formation by cytoplasmic Fab intrabodies against the matrix protein, p17. Molec. Med. 2:1997;96-110.
71. Beerli R.R., Wels W., Hynes N.E. Autocrine inhibition of the epidermal growth factor receptor by intracellular expression of a single-chain antibody. Biochem. Biophys. Res. Commun. 204:1994;666-672.
72. Biocca S., Pierandrei-Amaldi P., Campioni N., Cattaneo A. Intracellular immunization with cytosolic recombinant antibodies. Bio/Technology. 12:1994;396-399.
73. Biocca S., Pierandrei-Amaldi P., Cattaneo A. Intracellular expression of anti-p21ras single chain Fv fragments inhibits meiotic maturation of xenopus oocytes. Biochem. Biophys. Res. Commun. 197:1993;422-427.
74. Marasco W.A. Intrabodies: turning the humoral immune system outside in for intracellular immunization. Gene Ther. 4:1997;11-15.
75. Meydan N., Grunberger T., Dadi N., Shahar M., Arpala E., Lapidot Z., Leeder J.S., Freedman M., Cohen A., Gazit A., Levitzkl A., Rolfman C.M. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 379:1996;645-647.
76. Nielsen L.L., Dell J., Maxell E., Armstrong L., Maneval D., Catino J.J. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther. 4:1997;129-138.
77. Williams D.O., Gruentzig A.R., Kent K.M., Detre K.M., Kelsey S.F., To T. Efficacy of repeat percutaneous transluminal coronary angioplasty for coronary restenosis. Am. J. Cardiol. 53:1984;32C-35C.
78. Indolfi C., Esposito G., Di Lorenzo E., Rapacciuolo A., Feliciello A., Porcellini A., Avvedimento V.E., Cordorelli M., Chiariello M. Smooth muscle cell proliferation is proportional to the degree of balloon injury in a rat model of angioplasty. Circulation. 92:1995;1230-1235.
79. Ben-Av P., Crofford L.J., Wilder R.L., Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts of prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 372:1995;83-87.
80. Martiny-Baron G., Marme D. VEGF-mediated tumour angiogenesis: a new target for cancer therapy. Curr. Opin. Biotechnol. 6:1995;675-680.
81. Deng H-X., Hentati A., Tainer J.A., Iqbal Z., Cayabyab A., Hung W-Y., Getzoff E.D., Hu P., Herzfeldt B., Roos R.P., Warner C., Deng G., Soriano E., Smyth C., Parge H.E., Ahmed A., Roses A.D., Hallewell R.A., Pericak-Vance M.A., Siddique T. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science. 261:1993;1047-1051.
82. m for hydrogen peroxide. Proc. Natl. Acad. Sci. USA. 93:1996;5709-5714.
83. Hendriks L., Van Broeckhoven C. A β A4 amyloid precursor protein gene and Alzheimer's disease. Eur. J. Biochem. 237:1996;6-15.
84. Higgins L.S., Murphy G.M., Forno L.S., Catalano R., Cordell B. P3 β-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. Am. J. Pathol. 149:1996;585-596.
85. Teller J.K., Russo C., DeBusk L.M., Angelini G., Zaccheo D., Dagna-Bricarelli F., Scartezzini P., Bertolini S., Mann D.M.A., Tabaton M., Gambetti P. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nature Med. 2:1996;93-95.
86. Lippa C.F., Saunders A.M., Smith T.W., Swearer J.M., Drachman D.A., Ghetti L., Need D., Pulaski-Salo D., Dickson Y., Robitaille C., Bergeron B., Crain M.D., Benson Farrow M., Hyman B.T., George-Hyslop S.P., Roses A.D., Pollen D.A. Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology. 46:1996;406-412.
87. Kojima H., Inuzuka S., Miwa T., Furukawa S., Hayashi K., Kanegae Y., Saito I., Ohishi N., Takamori M., Yagi K. Construction and characterization of adenoviral vector expressing biologically active brain-derived neurotrophic factor. Biochem. Biophys. Res. Commun. 212:1995;712-717.
88. Sabate O., Horellou P., Vigne E., Colin P., Perricaudet M., Buc-Caron M.H., Mallet J. Transplantation to the rat brain of human neural progenitors that were genetically modified using adenoviruses. Nat. Genet. 9:1995;256-260.
89. Kennedy P.G., Steiner I. The use of Herpes simplex virus vectors for gene therapy in neurological diseases. Q.J. Med. 86:1993;697-702.
90. Marconi P., Krisky D., Oligino T., Poliani P.L., Ramkrishnan R., Goins W.F., Fink D.J., Glorioso J.C. Replication-defective Herpes simplex virus vectors for gene transfer in vivo. Proc. Natl. Acad. Sci. USA. 93:1996;11319-11320.
91. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. In vivo gene delivery and stable transduction of non-dividing cells by a lentiviral vector. Science. 272:1996;263-267.
92. Kleijmeer M.J., Kelly A., Geuze H.J., Slot J.W., Townsend A., Trowsdale J. Location of MHC-encoded transporters in the endoplasmic reticulum and cis-golgi. Nature. 357:1992;342-344.
93. Pinet V., Vergelli M., Martin R., Bakke O., Long E.O. Antigen presentation mediated by recycling of surface HLA-DR molecules. Nature. 375:1995;603-606.
94. Kotani H., Newton P.B. III, Zhang S., Chiang Y.L., Otto E., Weaver L., Blaese R.M., Anderson W.F., McGarrity G.J. Improved methods of retroviral vector transduction and production for gene therapy. Hum. Gene Ther. 5:1994;19-28.
95. Van Endert P.M., Liblau R.S., Patel S.D., Fugger L., Lopez T., Pociot F., Nerup J., McDevitt H.O. Major histocompatibility complex-encoded antigen processing gene polymorphism in IDDM. Diabetes. 43:1994;110-117.
96. Deacon T., Schumacher J., Dinsmore J., Thomas C., Palmer P., Kott S., Edge A., Penney D., Kassissieh S., Dempsey P., Isacson O. Histological evidence of fetal pig neural cell survival after transplanation into a patient with Parkinson's disease. Nat. Med. 3:1997;350-353.
97. Tavladoraki P., Benvenuto E., Trinca S., De Martinis D., Cattaneo A., Galeffi P. Transgenic plants expressing a functional single-chain Fv antibody are specifically protected from virus attack. Nature. 366:1993;469-472.
98. Benvenuto E., Tavladoraki P. Immunotherapy of plant viral diseases. Trends Microbiol. 3:1995;272-275.
99. Wall R.J., Rexroad C.E., Powell A., Shamay A., McKnight R., Hennighausen L. Synthesis and secretion of the mouse whey acidic protein in transgenic sheep. Transgenic. Res. 5:1996;67-72.
100. Archer J.S., Kennan W.S., Gould M.N., Bremel R.D. Human growth hormone (hGH) secretion in milk of goats after direct transfer of the hGH gene into the mammary gland by using replication-defective retrovirus vectors. Proc. Natl. Acad. Sci. USA. 91:1994;6840-6844.